Literature DB >> 15563358

The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development.

D K Walker1.   

Abstract

The pharmaceutical industry continues to look for ways to reduce drug candidate attrition throughout the drug discovery and development process. A significant cause of attrition is due to safety issues arising either as a result of animal toxicity testing or in the clinical programme itself. A factor in the assessment of safety during early drug development is the pharmacokinetic profile of the compound. This allows safety data to be considered in the light of systemic drug exposure and therefore permits a quantitative assessment. This is particularly applicable when assessing the risk of a new chemical entity (NCE) in relation to safety parameters such as QT interval prolongation, where free plasma concentrations have been shown to be predictive of this property in relation to potency in preclinical testing. Prior to actual human exposure it is therefore important to be able to predict reliably the pharmacokinetic behaviour of an NCE in order to place such safety findings into a quantitative risk context. The emerging science of pharmacogenetics is likely to further our ability to assess the risk of NCEs to populations and individuals due to genetic variance. The drug metabolizing enzyme CYP2D6 has been recognized as providing the potential to result in widely differing systemic drug exposure in the patient population due to polymorphic expression. Further knowledge is likely to add to our understanding of population differences in exposure and response and aid in the identification of risk factors. One potential strategy for improving the effectiveness of the drug discovery process is to obtain clinical pharmacokinetic data more rapidly in order to assess more accurately the potential for both efficacy and safety of an NCE. Whilst procedures and technologies are available that allow this on the microdose scale, it is important that we recognize potential limitations of these approaches in order that they can be applied beneficially.

Entities:  

Mesh:

Year:  2004        PMID: 15563358      PMCID: PMC1884636          DOI: 10.1111/j.1365-2125.2004.02194.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  63 in total

Review 1.  Role of transport proteins in drug absorption, distribution and excretion.

Authors:  A Ayrton; P Morgan
Journal:  Xenobiotica       Date:  2001 Aug-Sep       Impact factor: 1.908

2.  The value of improving the productivity of the drug development process: faster times and better decisions.

Authors:  Joseph A DiMasi
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Relative receptor expression is a determinant in xenobiotic-mediated CYP3A induction in rat and human cells.

Authors:  K Swales; N Plant; A Ayrton; S Hood; G Gibson
Journal:  Xenobiotica       Date:  2003-07       Impact factor: 1.908

Review 4.  Design of toxicokinetic studies.

Authors:  D A Smith; M J Humphrey; C Charuel
Journal:  Xenobiotica       Date:  1990-11       Impact factor: 1.908

5.  Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats.

Authors:  W Zhu; L Song; H Zhang; L Matoney; E LeCluyse; B Yan
Journal:  Drug Metab Dispos       Date:  2000-02       Impact factor: 3.922

Review 6.  Pharmacogenetics of the proton pump inhibitors: a systematic review.

Authors:  Elaine Chong; Mary H H Ensom
Journal:  Pharmacotherapy       Date:  2003-04       Impact factor: 4.705

7.  In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man--fact or myth.

Authors:  S Yee
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

8.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Authors:  Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

9.  Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.

Authors:  Michael W Jan; Troy L ZumBrunnen; Yusuf R Kazmi; Chad M VanDenBerg; Hiral D Desai; Donald J Weidler; David A Flockhart
Journal:  Drug Metabol Drug Interact       Date:  2002

10.  Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.

Authors:  Kazuishi Sekino; Takahiro Kubota; Yuko Okada; Yasuhiko Yamada; Koujirou Yamamoto; Ryuya Horiuchi; Kenjirou Kimura; Tatsuji Iga
Journal:  Eur J Clin Pharmacol       Date:  2003-09-19       Impact factor: 2.953

View more
  27 in total

Review 1.  Emerging therapeutic approaches in the management of retinal angiogenesis and edema.

Authors:  An Truong; Tien Y Wong; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2010-12-18       Impact factor: 4.599

2.  Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial.

Authors:  Anthony Cahn; Rashmi Mehta; Andrew Preece; James Blowers; Alison Donald
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

Review 3.  Pharmacogenomics: challenges and opportunities.

Authors:  Dan M Roden; Russ B Altman; Neal L Benowitz; David A Flockhart; Kathleen M Giacomini; Julie A Johnson; Ronald M Krauss; Howard L McLeod; Mark J Ratain; Mary V Relling; Huijun Z Ring; Alan R Shuldiner; Richard M Weinshilboum; Scott T Weiss
Journal:  Ann Intern Med       Date:  2006-11-21       Impact factor: 25.391

4.  Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: an integrated parent-metabolite model.

Authors:  Fátima Ortega; Antonio Quintana; Elena Suárez; John C Lukas; Nerea Jauregizar; Leire de la Fuente; Maria Luisa Lucero; Ana Gonzalo; Aurelio Orjales; Rosario Calvo
Journal:  Pharm Res       Date:  2005-09-20       Impact factor: 4.200

5.  Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.

Authors:  Kuresh A Youdim; Aref Zayed; Maurice Dickins; Alex Phipps; Michelle Griffiths; Amanda Darekar; Ruth Hyland; Odette Fahmi; Susan Hurst; David R Plowchalk; Jack Cook; Feng Guo; R Scott Obach
Journal:  Br J Clin Pharmacol       Date:  2008-02-14       Impact factor: 4.335

Review 6.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor.

Authors:  Iñaki F Trocóniz; Ilonka Zsolt; María J Garrido; Marta Valle; Rosa M Antonijoan; Manel J Barbanoj
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

8.  Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.

Authors:  L A Jopling; G F Watt; S Fisher; H Birch; S Coggon; M I Christie
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 9.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

10.  Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.

Authors:  Paraskevi F Katsakiori; Eirini P Papapetrou; George C Sakellaropoulos; Dimitrios S Goumenos; George C Nikiforidis; Christodoulos S Flordellis
Journal:  Int J Med Sci       Date:  2010-05-11       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.